The neuroprotective potential of rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in response to hypoxia in isolated bovine retina

Cellular Physiology and Biochemistry

Volumn 32, Issue 1, 2013, Pages 218-234

  Alt, Aizhan ^a   Hilgers, Ralf Dieter ^b   Tura, Aysegül ^a   Nassar, Khaled ^a   Schneider, Toni ^c   Hueber, Arno ^c   Januschowski, Kai ^d   Grisanti, Salvatore ^a   Lüke, Julia ^a   Lüke, Matthias ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Astrocyte; Cathepsin B; Electroretinogram; H 1152P; Microglia; M ller cell; Neuroprotection

Indexed keywords

CASPASE 3; H 1152P; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; B WAVE; BOVINAE; CELL DAMAGE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; GLIA CELL; GLIOSIS; HYPOXIA; IMMUNOHISTOCHEMISTRY; MICROGLIA; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUTRIENT SOLUTION; OSMOTIC PRESSURE; OXYGEN SATURATION; PHOTOSTIMULATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RETINA; TEMPERATURE;

BOVINAE; VERTEBRATA;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CATHEPSIN B; CATTLE; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; GLIOSIS; MICROGLIA; NEUROPROTECTIVE AGENTS; RETINA; RHO-ASSOCIATED KINASES;

EID: 84881162311     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350138     Document Type: Article

References (67)

1. Ames A: Energy requirements of CNS cells as related to their function and to their vulnerability to ischemia: a commentary based on studies on retina. Can J Physiol Pharmacol 1992;70:S158-S164.
2. Caprara C, Grimm C: From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res 2012;31:89-119.
3. Haugh LM, Linsenmeier RA, Goldstick TK: Mathematical models of the spatial distribution of retinal oxygen tension and consumption, including changes upon illumination. Ann Biomed Eng 1990;18:19-36.
4. Morgan JE: Circulation and axonal transport in the optic nerve. Eye (Lond) 2004;18:1089-1095.
5. Brown JL, Hill JH, Burke RE: The effect of hypoxia on the human electroretinogram. Am J Ophthalmol 1957;44:57-67.
6. Block F, Schwarz M: The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol 1998;30:281-287.
7. Tinjust D, Kergoat H, Lovasik JV: Neuroretinal function during mild systemic hypoxia. Aviat Space Environ Med 2002;73:1189-1194.
8. Kergoat H, Hérard ME, Lemay M: RGC sensitivity to mild systemic hypoxia. Invest Ophthalmol Vis Sci 2006;47:5423-5427.
9. Osborne NN, Melena J, Chidlow G, Wood JP: A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001;85:1252-1259.
10. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefánsson E: The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002;21:359-393.
11. Lange CA, Stavrakas P, Luhmann UF, de Silva DJ, Ali RR, Gregor ZJ, Bainbridge JW: Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol 2011;152:406-412.e3.
12. Harris A, Chung HS, Ciulla TA, Kagemann L: Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Prog Retin Eye Res 1999;18:669-687.
13. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG: Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-1038.
14. Whitcup SM: Clinical trials in neuroprotection. Prog Brain Res 2008;173:323-335.
15. Danesh-Meyer HV, Levin LA: Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 2009;148:186-191.
16. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K: Rho-associated kinase, a novel serine/ threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J 1996;15:2208-2216.
17. Riento K, Ridley AJ: Rocks: multifunctional kinases in cell behaviour. at Rev Mol Cell Biol 2003;4:446-456.
18. Fukata Y, Amano M, Kaibuchi K: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-39.
19. Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW: The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010;1:165-170.
20. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM: Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010;15622-629.
21. Shin HK, Salomone S, Ayata C: Targeting cerebrovascular Rho-kinase in stroke. Expert Opin Ther Targets 2008;12:1547-1564.
22. Satoh K, Fukumoto Y, Shimokawa H: Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011;301:H287-H296.
23. Hirooka Y, Shiokawa H: Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs 2005;5:31-39.
24. Sugiyama T, Shibata M, Kajiura S, Okuno T, Tonari M, Oku H, Ikeda T: Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci 2011;52:64-69.
25. Tokushige H, Waki M, Takayama Y, Tanihara H: Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res 2011;36:964-970.
26. Tan HB, Zhong YS, Cheng Y, Shen X: Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int J Ophthalmol 2011;4:652-657.
27. Watanabe M: Regeneration of optic nerve fibers of adult mammals. Dev Growth Differ 2010;52:567-576.
28. Rao VP, Epstein DL: Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21:167-177.
29. Fontainhas AM, Townes-Anderson E: RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment. Invest Ophthalmol Vis Sci 2011;52:579-587.
30. Kitaoka Y, Kitaoka Y, Kumai T, Lam TT, Kuribayashi K, Isenoumi K, Munemasa Y, Motoki M, Kobayashi S, Ueno S: Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res 2004;1018:111-118.
31. Tura A, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S: Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 2009;50:452-461.
32. Lingor P, Tönges L, Pieper N, Bermel C, Barski E, Planchamp V, Bähr M: ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008;131:250-263.
33. Hirata A, Inatani M, Inomata Y, Yonemura N, Kawaji T, Honjo M, Tanihara H: Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2008;246:51-59.
34. Yang C, Lafleur J, Mwaikambo BR, Zhu T, Gagnon C, Chemtob S, Di Polo A, Hardy P: The role of lysophosphatidic acid receptor (LPA1) in the oxygen-induced retinal ganglion cell degeneration. Invest Ophthalmol Vis Sci 2009;50:1290-1298.
35. Coleman K, Fitzgerald D, Eustace P, Bouchier-Hayes D: Electroretinography, retinal ischemia and carotid artery disease. Eur J Vasc Surg 1990;4:569-573.
36. Zager EL, Ames A: Reduction of cellular energy requirements. Screening for agents that may protect against CNS ischemia. J Neurosurg 1988;69:568-579.
37. Sasaki Y, Suzuki M, Hidaka H: The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-232.
38. Lüke M, Weiergräber M, Brand C, Siapich SA, Banat M, Hescheler J, Lüke C, Schneider T: The isolated perfused bovine retina-A sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 2005;16:27-36.
39. Wang L, Cioffi GA, Cull G, Dong J, Fortune B: Immunohistologic evidence for retinal glial cell changes in human glaucoma. Invest Ophthalmol Vis Sci 2002;43:1088-1094.
40. Heppner FL, Roth K, Nitsch R, Hailer NP: Vitamin E induces ramification and downregulation of adhesion molecules in cultured microglial cells. Glia 1998;22:180-188.
41. Boyd V, Cholewa OM, Papas KK: Limitations in the use of fluorescein diacetate/propidium iodide (FDA/ PI) and cell permeable nucleic acid stains for viability measurements of isolated islets of Langerhans. Curr Trends Biotechnol Pharm 2008;2:66-84.
42. Kilinc M, Gürsoy-Ozdemir Y, Gürer G, Erdener SE, Erdemli E, Can A, Dalkara T: Lysosomal rupture, necroapoptotic interactions and potential crosstalk between cysteine proteases in neurons shortly after focal ischemia. Neurobiol Dis 2010;40:293-302.
43. Carloni S, Carnevali A, Cimino M, Balduini W: Extended role of necrotic cell death after hypoxia-ischemiainduced neurodegeneration in the neonatal rat. Neurobiol Dis 2007;27:354-361.
44. Unal-Cevik I, Kilinç M, Can A, Gürsoy-Ozdemir Y, Dalkara T: Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. Stroke 2004;35:2189-2194.
45. Fletcher EL, Downie LE, Hatzopoulos K, Vessey KA, Ward MM, Chow CL, Pianta MJ, Vingrys AJ, Kalloniatis M, Wilkinson-Berka JL: The significance of neuronal and glial cell changes in the rat retina during oxygeninduced retinopathy. Doc Ophthalmol 2010;120:67-86.
46. Tezel G, Wax MB: Glial modulation of retinal ganglion cell death in glaucoma. J Glaucoma 2003;12:63-68.
47. Bringmann A, Wiedemann P: Müller glial cells in retinal disease. Ophhalmologica 2012;227:1-19.
48. Langmann T: Microglia activation in retinal degeneration. J Leukoc Biol 2007;81:1345-1351.
49. Birol G, Wang S, Budzynski E, Wangsa-Wirawan ND, Linsenmeier RA: Oxygen distribution and consumption in the macaque retina. Am J Physiol Heart Circ Physiol 2007;293:H1696-H1704.
50. Bui BV, Hu RG, Acosta ML, Donaldson P, Vingrys AJ, Kalloniatis M: Glutamate metabolic pathways and retinal function. J Neurochem 2009;111:589-599.
51. Bringmann A, Pannicke T, Biedermann B, Francke M, Iandiev I, Grosche J, Wiedemann P, Albrecht J, Reichenbach A: Role of retinal glial cells in neurotransmitter uptake and metabolism. Neurochem Int 2009;54:143-160.
52. Russo R, Rotiroti D, Tassorelli C, Nucci C, Bagetta G, Bucci MG, Corasaniti MT, Morrone LA: Identification of novel pharmacological targets to minimize excitotoxic retinal damage. Int Rev Neurobiol 2009;85:407-423.
53. Yamashita K, Kotani Y, Nakajima Y, Shimazawa M, Yoshimura S, Nakashima S, Iwama T, Hara H: Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007;1154:215-224.
54. Jeon S, Kim S, Park JB, Suh PG, Kim YS, Bae CD, Park J: RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate. J Biol Chem 2002;277:16576-16584.
55. Lewis G, Mervin K, Valter K, Maslim J, Kappel PJ, Stone J, Fisher S: Limiting the proliferation and reactivity of retinal Müller cells during experimental retinal detachment: the value of oxygen supplementation. Am J Ophthalmol 1999;128:165-172.
56. Kosako H, Amano M, Yanagida M, Tanabe K, Nishi Y, Kaibuchi K, Inagaki M: Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. J Biol Chem 1997;272:10333-10336.
57. Tramontina F, Leite MC, Cereser K, de Souza DF, Tramontina AC, Nardin P, Andreazza AC, Gottfried C, Kapczinski F, Gonçalves CA: Immunoassay for glial fibrillary acidic protein: antigen recognition is affected by its phosphorylation state. J Neurosci Methods 2007;162:282-286.
58. Ghiardi GJ, Gidday JM, Roth S: The purine nucleoside adenosine in retinal ischemia-reperfusion injury. Vision Res 1999;39:2519-2535.
59. Job C, Lagnado L: Calcium and protein kinase C regulate the actin cytoskeleton in the synaptic terminal of retinal bipolar cells. J Cell Biol 1998;143:1661-1672.
60. Shin T, Kim S, Ahn M, Kim H: An immunohistochemical study of protein kinase C in the bovine retina. J Vet Med Sci 2006;68:71-74.
61. Behrens UD, Borde J, Mack AF, Wagner HJ: Distribution of phosphorylated protein kinase C alpha in goldfish retinal bipolar synaptic terminals: control by state of adaptation and pharmacological treatment. Cell Tissue Res 2007;327:209-220.
62. Mueller BK, Mack H, Teusch N: Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-398
63. Salceda R, van Roosmalen GR, Jansen PA, Bonting SL, Daemen FJ: Nucleotide content of isolated bovine rod outer segments. Vision Res 1982;22:1469-1474.
64. Oberhoff P, Hockwin O: The ATP content of the retina in relation to the blood circulation. Albrecht von Graefes Arch Klin Exp Ophthalmol 1969;178:329-332.
65. Winkler BS: Glycolytic and oxidative metabolism in relation to retinal function. J Gen Physiol 1981;77:667-692.
66. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Eto Y, Morishige K, Matsumoto Y, Obara K, Nakayama K, Takahashi S, Takeshita A: Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol 2003;23:2209-2214.
67. Kaur C, Foulds WS, Ling EA: Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008;2:879-889.